Stifel reiterates Alkermes stock rating on pipeline confidence
Stifel reiterated a Buy rating and $63 price target for Alkermes (ALKS), citing confidence in its pipeline and upcoming clinical trial readouts. The stock has gained 49% year-to-date. Analysts highlight positive Phase Ib trial results for ALKS 7290 in ADHD and strong enrollment in Brilliance phase 3 trials. Other analysts have mixed ratings and targets, ranging from $50 to $65.
How this was made
The 30-second read
Why it matters
The reiterated Buy and higher target could attract new buying interest, but the market may be waiting for actual trial data before committing.
Market read
Analyst rating lift provides a short‑term catalyst for ALKS, but broader market impact is modest.
What to watch
Upcoming Phase 2 readouts could still miss expectations, creating downside risk.
Background
Alkermes is a mid‑cap biotech with multiple late‑stage trials in sleep disorders and ADHD. Recent analyst coverage has been mixed, with some raising targets and others staying neutral.
Ticker impact
Stifel reiterated a Buy rating and set a $63 price target for Alkermes after meeting executives, citing pipeline confidence.
likely upward pressure as the market prices in the higher target.
The new $63 target represents a 51% upside from current levels, providing a clear catalyst for buying.
Market effects
Positive outlook for biotech pipelines may lift peer sentiment in the sleep‑disorder and ADHD therapeutic space.
U.S. biotech sector may see modest gains.
Limited to investors tracking U.S. biotech equities.
Counterpoint
The rating reiteration may already be priced in, limiting upside potential.
Key entities
- companyAlkermes
Biopharmaceutical company developing treatments for sleep disorders and ADHD.
- analystStifel
Equity research firm that issued the reiterated rating.
